UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

Official title

A PhaseⅢ Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

Overview

This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

Interventions

• Drug UBT251 Injection 4.0 mg
  UBT251 Injection subcutaneously once weekly
• Drug UBT251 Injection 6.0 mg
  UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
• Drug UBT251 Injection Placebo 4.0 mg
  UBT251 Injection placebo subcutaneously once weekly
• Drug UBT251 Injection Placebo 6.0 mg
  UBT251 Injection placebo subcutaneously once weekly

Primary outcome measures

• Body Weight [Time frame: Week 52]

Secondary outcome measures (8)

• Waist Circumference [Time frame: Through study completion, an average of one year]
• BMI [Time frame: Through study completion, an average of one year]
• Systolic blood pressure [Time frame: Through study completion, an average of one year]
• Diastolic blood pressure [Time frame: Through study completion, an average of one year]
• HbA1c [Time frame: Week 12 、Week 24、Week 32、Week 52]
• Fasting Serum Lipids [Time frame: Week 12 、Week 24、Week 32、Week 52]
• SF-36 v2 scores [Time frame: Week 12 、Week 24、Week 32、Week 52]
• Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) scores [Time frame: Week 12 、Week 24、Week 32、Week 52]

Eligibility criteria

Inclusion Criteria：

• Age 18-75 years (inclusive) at the time of signing the informed consent form, regardless of gender;
• Body mass index (BMI) ≥28.0 kg/m² (obesity) or 24.0 kg/m² ≤ BMI <28.0 kg/m² (overweight) at screening, accompanied by by at least one of the following: a. Prediabetes, hypertension, dyslipidemia, or fatty liver; b. Weight-bearing joint pain; c. Obesity-induced dyspnea or obstructive sleep apnea syndrome;
• Self-reported having been on diet and exercise control for 3 months or more prior to screening, with body weight change ≤5 kg within the past 3 months;
• Trial participants (including their partners) have no plan for pregnancy from screening to 6 months after trial completion, and are willing to comply with the contraceptive measures specified in the trial, and have no plan for sperm or egg donation within 6 months after trial completion;
• Have been fully informed about this study and voluntarily sign a written informed consent form.

Exclusion criteria

• Known history of hypersensitivity to this study drug, its drug product excipients, or other similar active drugs;
• Any of the following medication history within 3 months before randomization:

• Treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors, amylin analogs, glucagon-like peptide-1 (GLP-1) analogs, glucose-dependent insulinotropic polypeptide (GIP) analogs, or glucagon (GCG) analogs;
• Use of over-the-counter weight-loss medications or appetite suppressants (including traditional Chinese medicine, dietary supplements, meal replacements), or prescription weight-loss medications (including but not limited to orlistat) or lipolytic injections (e.g., fat-dissolving injections);
• Use of medications that may affect body weight for a duration of 1 week or longer, or anticipated use during the trial, including but not limited to systemic glucocorticoid therapy (intravenous or oral administration, except for the following: topical external use or intra-articular, intranasal, ophthalmic, and inhaled glucocorticoids; short-term \[≤7 days\] systemic glucocorticoid use for prevention or treatment of non-autoimmune allergic diseases, upper respiratory tract infection);
• Treatment with tricyclic antidepressants, antipsychotics, or antiepileptic medications;
• Treatment with antidiabetic medications;
• History or evidence of any of the following diseases:

• Diagnosis of type 1, type 2 diabetes mellitus, or other types of diabetes mellitus (excluding history of gestational diabetes mellitus);
• Secondary obesity caused by diseases (including but not limited to elevated cortisol hormones \[e.g., Cushing's syndrome\], pituitary/hypothalamic injury, hypothyroidism, etc.) or medications (including but not limited to long-term glucocorticoid use, antidepressants, etc.);
• History of acute or chronic pancreatitis, or pancreatic surgery;
• History of symptomatic gallbladder disease within 1 year before screening (excluding trial participants who have undergone cholecystectomy \[completed at least 3 months before screening\] without long-term complications), or abdominal ultrasound at screening indicating large gallstones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the study physician determines may affect trial participant safety;
• Personal or family history (within first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
• Planned bariatric surgery during the trial or history of bariatric surgery, except for the following: a) acupuncture for weight loss or liposuction (e.g., abdominal liposuction) performed >1 year before screening; b) gastric banding, but the band was removed >1 year before screening; c) intragastric balloon, but the balloon was removed >1 year before screening; d) duodenal-jejunal bypass liner, but the liner was removed >1 year before screening;
• History of depression or severe mental illness (including but not limited to suicidal tendencies, schizophrenia, bipolar disorder, etc.);
• History of clinically significant cardiovascular or cerebrovascular disease within 6 months before screening;
• Severe retinal or macular disease (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) at screening or in the past, requiring urgent treatment as determined by the study physician;
• History of malignancy;
• Blood loss ≥400 mL (including trauma, blood draw, blood donation) within 3 months before screening, or receipt of blood or blood component transfusion;
• Lactating women or pregnant women;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Treatment

Study locations

China · 1 center

• Peking University People's Hospital — Beijing

Identifiers

NCT: NCT07648225 · TUL-UBT251（III-1）202601

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗